Loading clinical trials...

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome | Clinical Trials | Clareo Health

Approved For MarketingNCT01825395

Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).

Lead sponsor: University of Colorado, Denver•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

Not Yet Recruiting

A Study to Evaluate the Incidence of Clinically Suspicious Lambert-Eaton Myasthenic Syndrome (LEMS) in Subjects Diagnosed With Small Cell Lung Cancer (SCLC)

NCT07075627 · Small Cell Lung Cancer ( SCLC ), Lambert Eaton Myasthenic Syndrome (LEMS)

No Longer Available

Treatment of Lambert-Eaton Syndrome With 3,4 DAP

NCT00704925 · Lambert Eaton Myasthenic Syndrome

No Longer Available

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

NCT01378546 · Lambert Eaton Myasthenic Syndrome (LEMS)

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 6, 2021Terms

Trial snapshot

StatusAPPROVED_FOR_MARKETING

Phase—

Enrollment—

Start date—

Last updatedOct 6, 2021

Condition

Lambert Eaton Myasthenic Syndrome

Locations shown

University of Colorado

Aurora, Colorado

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 6, 2021Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions